Amphastar Pharmaceuticals, Inc.

AMPH ·Healthcare, Drug Manufacturers - General, United States

Net Cash Flow Breakdown

FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018 FY2017 FY2016 FY2015 FY2014 FY2013

Total Cash from Operations: $67.6M

Line Item	Value	% of Total
Capital Expenditures	$46.8M	69.3%
Net Cash Flow	$20.7M	30.7%